Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Last updated: May 6, 2025
Sponsor: Massachusetts General Hospital
Overall Status: Active - Recruiting

Phase

2

Condition

Lung Disease

Treatment

Dotarem

[68Ga]CBP8

Clinical Study ID

NCT05417776
2022P001087
  • Ages > 40
  • All Genders

Study Summary

The goal of this study is to investigate the ability of [68Ga]CBP8 to detect collagen deposition in early interstitial lung disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Group 1: First degree relatives of a family member with pulmonary fibrosis (n=8)

  • Age greater than 40 years

  • Have the ability to give written informed consent

  • First degree relative of a family member with pulmonary fibrosis

  • No known history of interstitial lung disease

  • No tobacco use within the prior 6 months.

Group 2: Subjects with interstitial lung abnormalities (ILAs) or interstitial lung disease (ILD) (n=22)

  • Age greater than 40 years

  • Have the ability to give written informed consent

  • ILAs or early ILD (defined by presence of reticular markings and / or tractionbronchiectasis but absence of a definite UIP pattern)

  • No tobacco use within the prior 6 months.

Exclusion

Exclusion criteria:

  • Electrical implants such as cardiac pacemaker or perfusion pump

  • Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses,artificial hearts, valves with steel parts, metal fragments, shrapnel, metallictattoos anywhere on the body, tattoos near the eye, or steel implants ferromagneticobjects such as jewelry or metal clips in clothing

  • Historical eGFR of less than 30 mL/min/1.73 m2

  • Pregnant or breastfeeding (a negative quantitative serum hCG pregnancy test isrequired for females having child-bearing potential before the subject canparticipate)

  • Claustrophobic reactions

  • Research-related radiation exposure exceeds current Radiology Department guidelines (i.e. 50 mSv in the prior 12 months)

  • Unable to lie comfortably on a bed inside the MR-PET

  • BMI > 33 (limit of the PET-MRI table)

  • Determined by the investigator(s) to be clinically unsuitable for the study (e.g.based on screening visit and/or during study procedures)

  • Pneumonia or other acute respiratory illness within 6 weeks of study entry

  • Parenchymal lung disease except for ILD/ILAs or emphysema

  • Acute exacerbation of ILD within the prior 6 months

  • VATS within the prior 6 months

  • Prior radiation therapy to the thorax

  • Known allergy to gadolinium.

Study Design

Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Dotarem
Phase: 2
Study Start date:
September 28, 2022
Estimated Completion Date:
April 01, 2026

Study Description

[68Ga]CBP8, is a PET imaging probe which selectively binds collagen type I. Collagen deposition is a pivotal event in the development of pulmonary fibrosis. [68Ga]CBP8 binds collagen with high affinity and has excellent pharmacological and pharmacokinetic profiles. [68Ga]CBP8 was shown in a mouse model to be effective for detecting lung fibrosis and response to treatment. In addition, [68Ga]CBP8 can detect increased collagen in the lungs of patients with idiopathic pulmonary fibrosis.

The goals of this study are:

  1. To determine whether collagen deposition as assessed by [68Ga]CBP8-PET MRI can detect increased collagen deposition in early interstitial lung disease and

  2. if the degree of [68Ga]CBP8 uptake predicts subsequent disease progression.

Connect with a study center

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.